Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 3/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.69 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.69 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.69 |
| ▸ | RELA | Q04206 | 1/20 | 0.69 |
| ▸ | PKM | P14618 | 1/20 | 0.64 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.58 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.56 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | OXTR | P30559 | 1/20 | 0.55 |
| ▸ | GFER | P55789 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.48 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.48 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15167777 | 0.84 | MAPK1 (0.51) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL6313505 | 0.84 | RAB9A (0.67) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL6052256 | 0.84 | MAPK1 (0.61) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL10365375 | 0.84 | PTPN1 (0.57) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL3296237 | 0.84 | PTPN1 (0.79) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL29209982 | 0.83 | NPC1 (0.51) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL29209980 | 0.83 | NPC1 (0.51) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL6180207 | 0.83 | MAPT (0.67) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL6319475 | 0.83 | MAPT (0.53) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 | |
| SCHEMBL27692438 | 0.83 | HSD11B1 (0.62) | NPC1RAB9AMAPTSMN1; SMN2NFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-2837627-B1 | AMIDOPYRIDINE DERIVATIVE, AND USE THEREOF | MITSUBISHI TANABE PHARMA CORP (JP) | 2017-01-18 | — | — | EP | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| US-9527859-B2 | Amidopyridine derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2016-12-27 | — | — | US | disclosed |
| EP-2595989-B1 | HETEROCYCLIC CHROMENE-SPIROCYCLIC PIPERIDINE AMIDES AS MODULATORS OF ION CHANNELS | VERTEX PHARMA (US) | 2016-07-13 | — | — | EP | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9150555-B2 | Amide derivative and use thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2015-10-06 | — | — | US | disclosed |
| US-9051296-B2 | Aryl carboxamide derivatives as TTX-S blockers | RAQUALIA PHARMA INC. (JP) | 2015-06-09 | — | — | US | disclosed |
| US-6974813-B2 | N-[(substituted five-membered di-or triaza diunsaturated ring) carbonyl] guanidine derivatives for the treatment of ischemia | WARNER-LAMBERT COMPANY (US) | 2005-12-13 | — | — | US | disclosed |
| EP-1176140-B1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | MITSUBISHI PHARMA CORP (JP) | 2004-12-29 | — | — | EP | disclosed |
| WO-2004084842-A2 | INHIBITORS OF CATHEPSIN S | IRM LLC (BM) | 2004-10-07 | — | — | WO | disclosed |
| US-20040198780-A1 | Inhibitors of cathepsin S | IRM LLC (BM) | 2004-10-07 | — | — | US | disclosed |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | PFIZER INC. | 2003-08-07 | — | — | US | disclosed |
| US-6492401-B1 | SODIUM HYDROGEN EXCHANGER TYPE 1 INHIBITORS; REDUCING PERIOPERATIVE MYOCARDIAL TISSUE DAMAGE | PFIZER, INC. | 2002-12-10 | — | — | US | disclosed |
| EP-1176140-A1 | AMIDE COMPOUNDS AND MEDICINAL USE THEREOF | Mitsubishi Pharma Corporation (JP) | 2002-01-30 | — | — | EP | disclosed |
| US-5888941-A | Carbozamides with antifungal activity | J. URIACH & CIA. S.A. (ES) | 1999-03-30 | — | — | US | disclosed |
| EP-0783502-A1 | NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1997-07-16 | — | — | EP | disclosed |
| WO-1997005131-A1 | NEW CARBOXAMIDES WITH ANTIFUNGAL ACTIVITY | J. URIACH & CIA. S.A. (ES) | 1997-02-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040198780-A1 | Inhibitors of cathepsin S | CTSS, CTSK, CTSE | NPC1 333/4885RAB9A 3129/4885MAPT 3007/4885 |
| US-20030149043-A1 | N-[(substituted five-membered di-or triaza diunsaturated ring)carbonyl] guanidine derivatives for the treatment of ischemia | NHERF1, SLC28A1, TNNI3 | NPC1 264/4885RAB9A 2117/4885MAPT 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.